Erratum: Phase i trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme (Journal of Neuro-Oncology (2012) 110 (257-264) DOI: 10.1007/s11060-012-0964-7);Phase i trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 110, Issue 2, 2012, Pages 257-264

  Grossmann, Kenneth F ^a   Colman, Howard ^b   Akerley, Wallace A ^a   Glantz, Michael ^c   Matsuoko, Yuko ^b   Beelen, Andrew P ^d   Yu, Margaret ^e   De Groot, John F ^f   Aiken, Robert D ^g   Olsen, Jeffery J ^h   Evans, Brent A ^d   Jensen, Randy L ^b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d Myrexis Inc   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f UNIVERSITY OF TEXAS   (United States)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h EMORY CLINIC   (United States)

Author keywords

Carboplatin; Glioblastoma multiforme; Vascular disrupting agent; Verubulin

Indexed keywords

BEVACIZUMAB; CARBAMAZEPINE; CARBOPLATIN; CIMETIDINE; CREMOPHOR; DEXAMETHASONE; DIPHENHYDRAMINE; GLUCOCORTICOID; PHENYTOIN; RANITIDINE; VERUBULIN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; COHORT ANALYSIS; COUGHING; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HYPESTHESIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR VASCULARIZATION;

EID: 84867874051     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1118-2     Document Type: Erratum

References (15)

1. Central Brain Tumor Registry of the United States (CBTRUS) (2011) 2011 CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. www.cbtrus.org/reports/reports. html. Accessed October 27, 2011
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
4. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-170
5. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740
6. Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S, Lukas P, English NM, Sirisoma N, Drewe J, Pervin A, Tseng B, Carlson RO, Pleiman CM (2007) MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res 67:5865-5871
7. Chang SM, Kuhn JG, Robins HI, Schold SC Jr, Spence AM, Berger MS, Mehta M, Pollack IF, Rankin C, Prados MD (2001) A phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. Cancer 91:417-422
8. Pleiman C, Valppu L, Bhoite L, Austin H, Taylor J, Baichwal V, Laughlin M, Carlson R (2007) Vascular disruption effects of MPC-6827. 98th AACR Annual Meeting, Los Angeles, CA
9. Jessing K, Mauck K, Bradford C, Patton JS, Reeves L, Bulka K, Zhang H, Sirosoma N, Cai SX, Mather G (2005) MPC-6827, a small molecule inhibitor of microtubule formation with high brain penetration: absorption, distribution, metabolism, excretion, and clinical considerations. AACR Annual Meeting. AACR, Anaheim, CA, p 801-b
10. Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R (2010) Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther 9:3410-3419
11. Warnick RE, Prados MD, Mack EE, Chandler KL, Doz F, Rabbitt JE, Malec MK (1994) A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 19:69-74
12. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH (1995) The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol 121:478-486
13. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
14. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
15. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK (2008) Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 90:89-97